

ASX ANNOUNCEMENT

27 November 2013

UPDATED STATEMENT OF COMMITMENTS

The Board of Cynata Therapeutics Limited (ASX: CYP) provide an updated statement of commitments based on the actual funds raised under the Prospectus of \$5.0 million. The Company intends to apply funds raised from the Offer in the 24 months following reinstatement to trading on the ASX as follows:

	Total \$
Existing cash reserves	1,700,000
Funds raised from the Offer	5,000,000
Total Funds Available	6,700,000
Expenses of the Offer and associated matters	512,635
Development of existing biodegradeable hygiene assets	200,000
Development of regulatory strategy	300,000
Pilot scale product manufacture	200,000
Manufacturing process development	1,500,000
Pre-clinical development	1,650,000
Clinical trial preparation	600,000
Contingency	400,000
Working capital and corporate administration	1,337,365
Total Funds Applied	6,700,000

Dr Ross Macdonald

Managing Director & Chief Executive Officer +61 412 119 343

About Cynata Therapeutics Limited

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus[™], originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus[™] technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus[™] does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus[™] MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

Cynata Therapeutics Limited – Suite 1, 1233 High Street, Armadale, Victoria 3143 - PO Box 7165, Hawthorn North, Victoria 3122 T: + 613 9824 5254 F: + 613 9822 7735 E: admin@cynata.com W: www.ecoquest.com.au OR www.cynata.com ABN - 98 104 037 372